Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

AgoneX Biopharmaceuticals - aVenture Company Research

AgoneX Biopharmaceuticals

AgoneX Biopharmaceuticals

AgoneX Biopharmaceuticals (formerly BioHealthonomics) is a clinical stage biopharmaceutical company developing AGX-201, a histamine receptor modulator for migraine prevention.

Santa Monica, CA, US🇺🇸

Founded

AgoneX Biopharmaceuticals, Inc. is a Delaware clinical stage biopharmaceutical company developing AGX-201, a subcutaneous histamine receptor modulator in Phase II testing for migraine prophylaxis. Incorporated as BioHealthonomics Inc, the company later adopted the AgoneX Biopharmaceuticals name and reports three issued U.S. patents and one issued Japanese patent on its platform.

The company states that an investigational new drug application positioned AGX-201 to begin development at Phase II for migraine prophylaxis, and frames its mast-cell histamine approach against CGRP-antagonist preventives. Longer-term plans extend the platform toward Alzheimer's disease, Parkinson's disease, multiple sclerosis, chronic traumatic encephalopathy, and amyotrophic lateral sclerosis.

AgoneX Biopharmaceuticals - Similar Companies

Agentix

agentixcorp.com

AgeneBio

agenebio.com

Axsome Therapeutics

axsome.com

AgoneX Biopharmaceuticals - Quick Facts

Who are AgoneX Biopharmaceuticals' competitors?

Companies similar to AgoneX Biopharmaceuticals include Agentix, AgeneBio, Axsome Therapeutics and AGI Biopharmaceuticals.

When was AgoneX Biopharmaceuticals founded?

AgoneX Biopharmaceuticals was founded in 2011.

Where is AgoneX Biopharmaceuticals' headquarters located?

AgoneX Biopharmaceuticals' headquarters is located in Santa Monica, CA, US.

When was AgoneX Biopharmaceuticals' last funding round?

AgoneX Biopharmaceuticals' most recent funding round was for $35.8k (USD) in February 2018.

How much disclosed funding has AgoneX Biopharmaceuticals raised?

AgoneX Biopharmaceuticals - Classification

Ownership: Private
Geographic Exposure: Global

Revenue: Recurring
Software

As of Feb 9, 2018, AgoneX Biopharmaceuticals has disclosed funding of $36.9k (USD). Undisclosed round amounts are excluded.

How many employees does AgoneX Biopharmaceuticals have?

AgoneX Biopharmaceuticals has 4 employees as of Oct 2, 2026.

Customer

Enterprise

Tags: Healthtech

SEC CIK: 1721429
EIN: 45-2980335

NAICS: 540000Professional, Scientific, and Technical Services
541714Research and Development in Biotechnology (except Nanobiotechnology)
541000Professional, Scientific, and Technical Services
541700Scientific Research and Development Services
541710Research and Development in the Physical, Engineering, and Life Sciences
SIC: 8700Engineering, Accounting, Research, Management, And Related Services
8730Research, Development, And Testing Services
8731Commercial Physical and Biological Research

Show 13 more industry codes

NAICS: 320000Manufacturing
325400Pharmaceutical and Medicine Manufacturing
620000Health Care and Social Assistance
325000Chemical Manufacturing
623000Nursing and Residential Care Facilities
325410Pharmaceutical and Medicine Manufacturing
325412Pharmaceutical Preparation Manufacturing
SIC

AGI Biopharmaceuticals

Oxeia Biopharmaceuticals

oxeiabiopharma.com

Aggamin

BioIntervene

Axikin Pharmaceuticals

axikin.com

Adrx

adrxpharma.com

Aeovian Pharmaceuticals

aeovian.com

Axonia Medical

Biohaven

biohaven.com

AgGenetics

AcelRx Pharmaceuticals

AGY Therapeutics

2800

Chemicals And Allied Products

8000Health Services

2830Drugs

8040Offices And Clinics Of Other Health Practitioners

2834Pharmaceutical Preparations

8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified

AgoneX Biopharmaceuticals - Products & Services

AGX-201
AGX-201 is AgoneX Biopharmaceuticals' subcutaneous histamine dihydrochloride candidate in Phase II testing for migraine prophylaxis.
Competing Products